Quantcast
Last updated on April 24, 2014 at 5:18 EDT

Latest Isis Stories

2014-02-27 12:25:04

The mobile wallet landscape will undergo more change and innovation in the next two years than it has since its inception. In an already crowded marketplace with no single vendor leading the charge, Yankee Group identifies which providers have the long-term vision to succeed. BOSTON, Feb. 27, 2014 /PRNewswire/ -- The U.S. mobile payment landscape is currently in a state of flux: Although two-thirds of consumers are interested in learning more about transitioning to a mobile wallet platform,...

2014-02-26 12:30:37

LONDON, Feb. 26, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Consumer Payments Competitor Tracker The global consumer payments market is a highly dynamic and competitive space, which means that it is crucially important to stay on top of key developments. Datamonitor's Global Consumer Payments Competitor Tracker does just that, providing expert analysis and opinion on the key strategic moves of leading competitors in the consumer payments...

2014-02-25 08:31:09

CARLSBAD, Calif., Feb. 25, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Cowen and Company 34(th) Annual Health Care Conference on Tuesday, March 4, 2014 at 8:40 a.m. ET in Boston, MA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2014-02-21 16:23:09

On track to initiate Phase 3 study in infants with SMA in the middle of this year CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMN(Rx) in infants with spinal muscular atrophy (SMA). To date, all four infants in the 6 mg cohort have been in the study for over six months and are now approximately nine and a half to 16 months in age with an average age...

2014-02-21 08:25:03

Average increase of 3.7 points observed in muscle function score in SMA children treated with 9 mg of ISIS-SMN Rx CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced top-line results from an ongoing open-label, multiple-dose study of ISIS-SMN(Rx )in children with spinal muscular atrophy (SMA). In this study, ISIS-SMN(Rx) was well tolerated at all dose levels in children with SMA. Consistent with single-dose observations,...

2014-02-20 16:26:51

CARLSBAD, Calif., Feb. 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' 2013 Financial Results and Highlights Conference Call When: Friday, February 28 at 11:30 a.m. ET /8:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our...

2014-02-19 08:30:06

CARLSBAD, Calif., Feb. 19, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 RBC Capital Markets Global Healthcare Conference on Wednesday, February 26, 2014 at 2:05 p.m. ET in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20130807/LA60006LOGO) A live audio webcast of the presentation will be available on the "Investors & Media" section of the...

2014-02-14 16:24:52

CARLSBAD, Calif., Feb. 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ISIS-TTR(Rx) for designation as an orphan medicinal product for the treatment of ATTR-Amyloidosis to the European Commission (EC). The opinion will be subject to review by the EC, which ultimately grants the decision on orphan drug designation. ATTR-Amyloidosis, or TTR amyloidosis,...

2014-02-13 08:30:17

--Isis will receive $9.3 million in milestone payments -- CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA). Isis also announced today that the first child was dosed in an open-label extension study, which is being offered to those children with SMA who have completed dosing in...

2014-02-07 23:23:11

Open Mobile Media will bring together 250+ industry leaders including Citi Bank, Qualcomm, Plink, Deloitte and more at The Wallet Wars USA Conference & Exhibition (June 19-20, New York, USA) to dissect the future of the mobile wallet. (PRWEB) February 07, 2014 In June 2013, Gartner forecast that the total value of worldwide mobile payment transactions (both remote and in-person) will reach $235 billion in 2013, a 44% increase from 2012. Gartner also forecast the total value of mobile...